Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fesoterodine
- Development stage
- Approved
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Fesoterodine is a small molecule antimuscarinic agent used to treat overactive bladder in adults and neurogenic detrusor overactivity in pediatric patients aged 6 years and older weighing more than 25 kg. It works by competitively antagonizing muscarinic acetylcholine receptors (M1–M5), leading to relaxation of the bladder muscle, increased bladder capacity, and reduced symptoms of urinary frequency, urgency, and urge incontinence. Fesoterodine is administered orally as an extended-release tablet. Its active metabolite is 5-hydroxymethyltolterodine.
- Brand names
- Toviaz
- Other names
- fesoterodine fumarate
02
Targets
CHRM2 (M2)CHRM3 (M3)M1 (Muscarinic acetylcholine receptor M1)CHRM4 (M4)CHRM5 (M5)
Beyond the preview
Go deeper on fesoterodine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fesoterodine.